There is currently no FDA-approved antiviral drug designed to treat active RSV infection in adults, a fact that surprises many caregivers and families navigating respiratory illness season with vulnerable older relatives. What the medical landscape does offer, as of early 2026, is a growing arsenal of preventive tools — vaccines and monoclonal antibodies — that can dramatically reduce the risk of severe RSV disease before it takes hold. For adults aged 50 and older, particularly those living with dementia or residing in long-term care facilities, these preventive options represent meaningful protection against a virus that hospitalizes an estimated 60,000 to 160,000 U.S. adults aged 65 and older each year and kills between 6,000 and 10,000 of them annually.
The distinction between prevention and treatment matters enormously for dementia caregivers. A person with Alzheimer’s disease or another form of cognitive decline who contracts RSV may struggle to communicate worsening symptoms, making prevention the far more practical strategy. Three vaccines — GSK’s Arexvy, Pfizer’s Abrysvo, and Moderna’s mResvia — are now approved for various adult age groups, while experimental antivirals like EDP-938 and sisunatovir remain in clinical trials. This article breaks down who qualifies for each option, what the pipeline looks like for actual treatment drugs, and what caregivers of older adults with cognitive impairment should know heading into the next respiratory season.
Table of Contents
- What New Drugs Target RSV, and Who Actually Qualifies for Protection?
- Why There Is Still No Approved Antiviral for Active RSV in Adults
- The Antiviral Pipeline — What Is Coming and How Soon
- Comparing the Three Adult RSV Vaccines — Which One Fits Your Situation
- RSV Risks That Dementia Caregivers Underestimate
- What Long-Term Care Facilities Should Be Doing About RSV
- Looking Ahead — When Treatment Might Finally Catch Up to Prevention
- Conclusion
- Frequently Asked Questions
What New Drugs Target RSV, and Who Actually Qualifies for Protection?
The word “treatment” gets used loosely in headlines about RSV, but it is important to understand what is actually available. The FDA-approved options fall into two categories: vaccines for adults and monoclonal antibodies for infants. For adults, arexvy from GSK is approved for those aged 50 and older who are at increased risk, Abrysvo from Pfizer covers adults 60 and older as well as pregnant individuals, and Moderna’s mResvia received expanded approval in June 2025 to include adults aged 18 to 59 at increased risk. that Moderna expansion was significant — it marked the first time younger adults with chronic conditions could access an RSV vaccine. For the older adult population most relevant to dementia care, eligibility is fairly straightforward. Adults 60 and older can receive either Arexvy or Abrysvo.
Those between 50 and 59 need to demonstrate increased risk — chronic heart or lung disease, diabetes, immunocompromised status, or residence in a long-term care facility all qualify. GSK has also filed for expanded Arexvy approval down to ages 18 to 49 at increased risk, with an FDA decision expected in the first half of 2026. A person with early-onset dementia in their 50s who also has cardiovascular disease, for instance, would likely qualify under current guidelines. But someone in their 40s with dementia alone may need to wait for the expanded approval. On the infant side, two monoclonal antibodies now exist: Beyfortus (nirsevimab) from AstraZeneca and Sanofi, and the newer ENFLONSIA (clesrovimab) from Merck. ENFLONSIA demonstrated an 84.3% reduction in RSV-associated hospitalizations over five months in clinical trials and is given as a single 105 mg dose. While these infant products are not directly relevant to elderly dementia care, they matter to multigenerational households where a grandparent with cognitive decline lives alongside a newborn — reducing RSV transmission in the home protects everyone.
Why There Is Still No Approved Antiviral for Active RSV in Adults
Despite decades of research, the only antiviral currently used to treat active RSV infection is aerosolized ribavirin, and its application is limited almost entirely to hospitalized children with severe disease. Its clinical benefit remains debated even in that narrow context. For adults who develop RSV — including the tens of thousands of older adults hospitalized each year — treatment remains supportive: fluids, oxygen, and management of complications. There is no pill or infusion a doctor can prescribe to fight the virus directly once symptoms appear. This gap is particularly concerning for people with dementia. Respiratory infections in cognitively impaired adults tend to present atypically.
A person with moderate Alzheimer’s may not report a sore throat, may not recognize that their breathing has become labored, and may become acutely confused in ways that mimic a dementia flare rather than an infection. By the time a caregiver or clinician identifies RSV as the culprit, the window for any hypothetical early-intervention antiviral has often closed. However, if a caregiver notices sudden behavioral changes, increased agitation, or new confusion during RSV season — typically October through March in most of the U.S. — they should request respiratory virus testing rather than assuming the change is purely neurological. The lack of an approved adult antiviral also means that current RSV management in long-term care facilities relies heavily on infection control: isolating symptomatic residents, enforcing hand hygiene, and now vaccinating eligible individuals. For facility administrators and family caregivers alike, the practical takeaway is that prevention through vaccination is not merely preferable — it is, at present, the only pharmacological defense available.
The Antiviral Pipeline — What Is Coming and How Soon
Two experimental antivirals are worth watching. EDP-938, developed by Enanta Pharmaceuticals, is an oral once-daily RSV nucleoprotein inhibitor that showed promising results in Phase II human challenge trials — participants had undetectable RSV RNA by Day 5 of treatment. The drug also demonstrated a high barrier to resistance, meaning the virus is less likely to mutate around it. However, when tested against community-acquired mild RSV infections, EDP-938 did not meet its primary symptom-score endpoint. In plain terms, the drug appeared to suppress the virus effectively but did not translate that suppression into noticeably faster symptom relief in people with mild illness. This is a meaningful limitation, because most RSV infections in otherwise healthy adults are mild.
The second candidate, sisunatovir (also known as RV521), is a small-molecule inhibitor that targets the RSV F protein. It has demonstrated potent activity against both RSV A and RSV B clinical isolates in laboratory testing and is in clinical development, though it remains earlier in the pipeline than EDP-938. Neither drug is close to FDA approval as of early 2026, and even optimistic timelines suggest several more years of clinical trials before an oral antiviral for RSV reaches the market. For dementia caregivers, this pipeline is a reason for cautious hope but not a reason to delay vaccination. A person with Lewy body dementia and chronic obstructive pulmonary disease, for example, cannot afford to wait for a treatment drug that may be three to five years away when a preventive vaccine is available now. The pipeline drugs will likely matter most for breakthrough infections — cases where a vaccinated person still contracts RSV — and for populations where vaccination is contraindicated.
Comparing the Three Adult RSV Vaccines — Which One Fits Your Situation
Choosing among Arexvy, Abrysvo, and mResvia involves weighing age eligibility, risk factors, and vaccine platform. Arexvy uses an adjuvanted protein-based approach and is currently the broadest option for older adults, covering those 50 and older at increased risk. Abrysvo, also protein-based, is approved for adults 60 and older and has the unique additional indication for pregnant individuals seeking to protect their newborns. Moderna’s mResvia uses mRNA technology — the same platform behind the company’s COVID-19 vaccine — and as of June 2025 covers the widest age range, including adults 18 to 59 at increased risk. For a 72-year-old with vascular dementia living in an assisted living facility, any of the three approved vaccines would be appropriate, and the choice may come down to what the facility’s pharmacy stocks or what the individual’s physician recommends.
For a 55-year-old with frontotemporal dementia and diabetes, Arexvy and mResvia are both options, while Abrysvo would not apply until age 60. One practical consideration for dementia caregivers: all three vaccines are single-dose injections, which simplifies administration for individuals who may become agitated during medical procedures. There is no need for a multi-dose series or return visits. The tradeoff worth discussing with a physician is timing. RSV season peaks between December and February in most regions, and vaccination ideally occurs before the season begins. A caregiver who waits until January to inquire about vaccination has already missed the window of greatest benefit, though late vaccination still offers some protection for the remainder of the season.
RSV Risks That Dementia Caregivers Underestimate
RSV is often dismissed as a childhood illness, and this perception creates dangerous blind spots in adult care. Among U.S. adults 65 and older, RSV causes an estimated 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths annually — numbers that rival influenza in bad years. Older adults with neurological conditions face compounded risk: cognitive impairment makes it harder to maintain hydration during illness, dementia-related swallowing difficulties increase aspiration pneumonia risk during respiratory infections, and the delirium triggered by RSV can accelerate cognitive decline in ways that may not fully reverse after the infection clears. A limitation that caregivers should understand is that vaccination does not eliminate RSV risk entirely. The vaccines reduce the likelihood of severe lower respiratory tract disease, but a vaccinated person can still contract RSV and experience upper respiratory symptoms.
For someone with advanced dementia who cannot reliably report symptoms, caregivers should continue monitoring for signs of respiratory distress — rapid breathing, flaring nostrils, refusal to eat or drink, or unusual lethargy — even after vaccination. The vaccine is a layer of protection, not a guarantee, and it works best as part of a broader strategy that includes hand hygiene, limiting exposure to symptomatic visitors, and prompt medical evaluation when respiratory symptoms appear. Another underappreciated risk involves the household. RSV spreads efficiently through respiratory droplets and contaminated surfaces. A caregiver who develops what feels like a common cold may actually be carrying RSV and shedding virus to the person they are caring for. Caregivers of high-risk older adults should consider their own vaccination status and practice respiratory hygiene — covering coughs, washing hands before direct care — particularly during peak season.
What Long-Term Care Facilities Should Be Doing About RSV
Congregate living settings are where RSV does its worst damage among older adults. Facilities that have adopted routine RSV vaccination for eligible residents report meaningful reductions in respiratory hospitalizations, though published data on facility-level outcomes is still emerging. The practical challenge is implementation: unlike influenza vaccination, which has decades of institutional momentum in nursing homes, RSV vaccination is new enough that many facilities have not yet built it into their standard admission or seasonal protocols.
Family members serving as healthcare proxies for residents with dementia should proactively ask facility administrators whether RSV vaccination is offered, which vaccine the facility uses, and whether their loved one has been assessed for eligibility. In facilities where vaccination is not yet standard, a family member can request that the resident’s attending physician order the vaccine individually. This is one area where caregiver advocacy directly translates to reduced hospitalization risk.
Looking Ahead — When Treatment Might Finally Catch Up to Prevention
The current landscape, where RSV prevention options have leapt ahead of treatment options, is unlikely to remain static. The clinical development of EDP-938 and sisunatovir, along with other candidates in earlier stages, suggests that an oral antiviral for RSV could reach the market within the next several years. If EDP-938’s antiviral potency can be paired with clinical symptom improvement in larger trials, it would represent the first direct treatment option for adults with active RSV infection — a development that would be particularly meaningful for immunocompromised individuals and those in whom vaccination is less effective.
For now, the most important action a dementia caregiver can take is ensuring that eligible older adults receive one of the approved RSV vaccines before the next respiratory season begins. The science of RSV prevention has moved remarkably fast in the past two years, and the gap between what is available and what many older adults actually receive remains wide. Closing that gap, one conversation with a physician at a time, is where the real impact lies.
Conclusion
RSV remains a serious and underrecognized threat to older adults, particularly those living with dementia or other conditions that compromise their ability to fight respiratory infections and communicate symptoms. While no antiviral drug is yet approved to treat active RSV infection in adults, three vaccines — Arexvy, Abrysvo, and mResvia — now offer meaningful prevention for adults across a range of ages and risk profiles. Monoclonal antibodies like ENFLONSIA and Beyfortus protect infants, reducing household transmission risk in multigenerational homes.
Caregivers should not wait for the next generation of antiviral treatments to act. Vaccination before RSV season, vigilant symptom monitoring during it, and advocacy within long-term care facilities are the practical steps available right now. As the treatment pipeline matures, the options will only improve — but the protection available today is already substantial enough to prevent thousands of hospitalizations and deaths among the people most vulnerable to this virus.
Frequently Asked Questions
Is there a pill I can give my parent with dementia if they catch RSV?
No. As of early 2026, there is no FDA-approved oral antiviral for treating active RSV infection in adults. Treatment for RSV in older adults is supportive — fluids, oxygen, and monitoring. The only antiviral used for RSV treatment is aerosolized ribavirin, which is limited to hospitalized children with severe disease.
At what age can an older adult get an RSV vaccine?
Pfizer’s Abrysvo is approved for adults 60 and older. GSK’s Arexvy covers adults 50 and older at increased risk. Moderna’s mResvia was expanded in June 2025 to include adults 18 to 59 at increased risk. Most older adults with dementia will qualify under one or more of these options.
Does having dementia alone qualify someone as “high risk” for RSV vaccination?
Dementia itself is not explicitly listed as a qualifying condition in most RSV vaccine guidelines. However, many people with dementia also have comorbidities — heart disease, lung disease, diabetes — that do qualify them. Residence in a long-term care facility is also a qualifying risk factor. Speak with a physician about individual eligibility.
Can RSV make dementia worse?
Respiratory infections like RSV commonly trigger delirium in people with dementia, which can cause a sudden, severe worsening of confusion and function. While delirium is technically reversible, some individuals do not return to their pre-illness baseline, effectively experiencing a step-down in cognitive function after a serious infection.
Should dementia caregivers themselves get vaccinated against RSV?
Caregivers under 50 without chronic conditions may not yet qualify for RSV vaccination, depending on the vaccine. However, Moderna’s mResvia now covers adults 18 to 59 at increased risk, and GSK’s application to expand Arexvy to ages 18 to 49 is pending FDA review. Caregivers should discuss eligibility with their own physicians and, at minimum, practice rigorous respiratory hygiene during RSV season.
How effective are the infant monoclonal antibodies at reducing household RSV spread?
ENFLONSIA demonstrated an 84.3% reduction in RSV-associated hospitalizations among infants over five months. While these products are designed to protect the infant rather than prevent transmission per se, reducing severe infant infection in a household with a vulnerable older adult lowers the overall viral burden in the home.
